Why has Pfizer stock floundered?
Pfizer chief corporate affairs chief Sally Sussman shares lessons from how the company responded to the global pandemic. INC. TODAY'S MUST READS: New Research: Status Reports Can Make Teams Less Effective INC. TODAY'S MUST READS: How to Stay Innovative ...
Should I buy Pfizer Inc. (PFE)?
Pfizer Inc. (NYSE:PFE) released its full-year results, but the market seems to be already pricing-in a decline. Shares are down 4.4% to US$51.5 in the past week, and the stock is currently in the red. Markets are forward-looking, and the price decline ...
Where will Pfizer be in 5 years?
Pfizer’s early data showed two of the extra-low doses were safe for kids under 5 and strong enough to give good protection to babies as young as 6 months. But once tots reached the preschool age -- the 2- to 4-year-olds -- two shots didn’t rev up ...
Why is PFE dropping?
There were a couple of other factors that help explain the stock's drop. Late in the month, the company announced that it was ending the clinical development of vupanorsen, a drug thought to be a possible therapy to reduce cardiovascular risk from hypertriglyceridemia.
There's still uncertainty about the big drugmaker's future COVID-19 vaccine revenue
Pfizer ( PFE -1.09% ) recently announced very good first-quarter results. Revenue and profits soared. The big drugmaker even raised its full-year guidance. However, its share price barely moved.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
Why is Pfizer down?
Another reason Pfizer has been down is that they've had some clinical setbacks. They really had high hopes for breast cancer drug Ibrance, and early breast cancer setting, and had a couple of clinical studies that didn't pan out so well, and so that's been another negative impact on the stock.
Why is Pfizer weighing down?
One of the big reasons is that Pfizer has been just weighed down by their legacy drugs, Lyrica, other drugs that have lost patent exclusivity, and it's really just weighed on their revenue growth, earnings growth, and that's been a big problem.
NYSE: PFE
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Pfizer is on a roll right now. But the stock still faces risks
Pfizer ( PFE -0.76% ) delivered sizzling growth in the second quarter. Its COVID-19 vaccine continues to rake in billions of dollars. Several of the company's other products are generating strong sales growth. Pfizer's dividend is attractive. In this Motley Fool Live video recorded on Aug.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
There are several potential reasons why investors didn't cheer the companies' great news more loudly
We've known for a while that the COVID-19 vaccine developed by Pfizer ( PFE -2.89% ) and BioNTech ( BNTX 5.62% ) was highly effective in individuals ages 16 and up. The two partners recently announced an impressive 100% efficacy for the vaccine in children between the ages of 12 and 15.
NYSE: PFE
Keith Speights: Pfizer and BioNTech announced results from their phase 3 study and this study showed 100% efficacy for their COVID vaccine, BNT162b2. Kids ages 12 through 15. So the companies plan to move pretty quickly to file for Emergency Use Authorization.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
How many shots of Pfizer will be required in 2021?
The companies intend to manufacture up to 50 million doses this year, and as much as 1.3 billion doses in 2021. Two shots of the vaccine will be required per person. While Pfizer stock was up by almost 8% following the news, we think it’s unlikely that the vaccine will meaningfully move the needle for the company for multiple reasons.
Can Pfizer be refrigerated?
On the other hand, vaccines being developed by the likes of Oxford- AstraZeneca, Novavax, and others can be held at regular refrigerated temperatures. This could potentially limit the use of Pfizer’s vaccine to clinics and hospitals that have the appropriate storage facilities.
Is Pfizer working with Biontech?
Pfizer (PFE) is working with German partner BioNTech on a Covid-19 vaccine. The company is likely to have efficacy data from late-stage trials available shortly. The company could supply about 40 million doses in the United States in 2020 if the data is positive and regulators approve the vaccine. The stock is down by about -7.6% this year.
